The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy
Renin-angiotensin-aldosterone system inhibitors prevent the progression of kidney disease in patients with diabetic nephropathy, and we studied how that benefit varies by the type of diabetes and baseline urinary albumin. We pooled data from 49 randomized controlled trials in a meta-analysis using t...
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
2012
|
| _version_ | 1826299797460484096 |
|---|---|
| author | Taylor, K Stevens, R Blacklock, C Roberts, N Pugh, C Farmer, A Hirst, J |
| author_facet | Taylor, K Stevens, R Blacklock, C Roberts, N Pugh, C Farmer, A Hirst, J |
| author_sort | Taylor, K |
| collection | OXFORD |
| description | Renin-angiotensin-aldosterone system inhibitors prevent the progression of kidney disease in patients with diabetic nephropathy, and we studied how that benefit varies by the type of diabetes and baseline urinary albumin. We pooled data from 49 randomized controlled trials in a meta-analysis using the ratio of endpoint urinary albumin levels in those treated compared to those untreated with renin-angiotensin-aldosterone system inhibitors in both fixed- and random-effects models. The urinary albumin excretion for treated microalbuminuric patients with Type 1 diabetes was on average 60% lower at the end of the trial compared with patients not treated with renin-angiotensin- aldosterone system inhibitors using the fixed-effects model and 67% lower using the random-effects model. There was no significant effect of treatment in patients with normal albumin excretion. For normoalbuminuric patients with Type 2 diabetes, urinary albumin excretion was on average 12% lower after treatment using the fixed-effects model compared to 21% lower using the random-effects model. For microalbuminuric patients, urinary albumin excretion was on average 23% lower using the fixed-effects model and 27% lower using the random-effects model. Thus, renin-angiotensin-aldosterone system inhibition reduced urinary albumin excretion for Type 1 diabetic patients with micro-, but not those with normoalbuminuria. Treatment reduced urinary albumin excretion for Type 2 diabetic patients with and without microalbuminuria. © 2012 International Society of Nephrology. |
| first_indexed | 2024-03-07T05:07:25Z |
| format | Journal article |
| id | oxford-uuid:da65d651-923d-4b08-b20c-cf97c42e3b82 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:07:25Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:da65d651-923d-4b08-b20c-cf97c42e3b822022-03-27T09:02:57ZThe impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:da65d651-923d-4b08-b20c-cf97c42e3b82EnglishSymplectic Elements at Oxford2012Taylor, KStevens, RBlacklock, CRoberts, NPugh, CFarmer, AHirst, JRenin-angiotensin-aldosterone system inhibitors prevent the progression of kidney disease in patients with diabetic nephropathy, and we studied how that benefit varies by the type of diabetes and baseline urinary albumin. We pooled data from 49 randomized controlled trials in a meta-analysis using the ratio of endpoint urinary albumin levels in those treated compared to those untreated with renin-angiotensin-aldosterone system inhibitors in both fixed- and random-effects models. The urinary albumin excretion for treated microalbuminuric patients with Type 1 diabetes was on average 60% lower at the end of the trial compared with patients not treated with renin-angiotensin- aldosterone system inhibitors using the fixed-effects model and 67% lower using the random-effects model. There was no significant effect of treatment in patients with normal albumin excretion. For normoalbuminuric patients with Type 2 diabetes, urinary albumin excretion was on average 12% lower after treatment using the fixed-effects model compared to 21% lower using the random-effects model. For microalbuminuric patients, urinary albumin excretion was on average 23% lower using the fixed-effects model and 27% lower using the random-effects model. Thus, renin-angiotensin-aldosterone system inhibition reduced urinary albumin excretion for Type 1 diabetic patients with micro-, but not those with normoalbuminuria. Treatment reduced urinary albumin excretion for Type 2 diabetic patients with and without microalbuminuria. © 2012 International Society of Nephrology. |
| spellingShingle | Taylor, K Stevens, R Blacklock, C Roberts, N Pugh, C Farmer, A Hirst, J The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title | The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title_full | The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title_fullStr | The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title_full_unstemmed | The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title_short | The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| title_sort | impact of renin angiotensin aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy |
| work_keys_str_mv | AT taylork theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT stevensr theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT blacklockc theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT robertsn theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT pughc theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT farmera theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT hirstj theimpactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT taylork impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT stevensr impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT blacklockc impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT robertsn impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT pughc impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT farmera impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy AT hirstj impactofreninangiotensinaldosteronesysteminhibitorsontype1andtype2diabeticpatientswithandwithoutearlydiabeticnephropathy |